Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients

Alberico L. Catapano, Michael H. Davidson, Christie M. Ballantyne, William E. Brady, Russell A. Gazzara, Joanne E. Tomassini, Andrew M. Tershakovec

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Objective: assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. Research design and methods: Double-blind, multicenter, 6-week, parallel-group study in hypercholesterolemic patients (n = 2959). Patients were randomized based on stratification by low-density lipoprotein cholesterol (LDL-C) levels to ezetimibe/simvastatin or rosuvastatin, respectively, at the usual starting (10/20 or 10 mg/day), the next highest (10/40 or 20 mg/day), and maximum doses (10/80 or 40 mg/day). Results: At all doses and across doses, ezetimibe/simvastatin reduced LDL-C levels significantly more (52-61%) than rosuvastatin (46-57%; p ≤, 0.001). Significantly greater percentages of all patients (p <0.001) and high risk patients (p ≤, 0.005) attained LDL-C levels <70 mg/dL (1.8 mmol/L) following ezetimibe/simvastatin treatment compared with rosuvastatin at the prespecified doses and across doses. Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p <0.001), non-high-density lipoprotein cholesterol (p <0.001), lipid ratios (p

Original languageEnglish
Pages (from-to)2041-2053
Number of pages13
JournalCurrent Medical Research and Opinion
Volume22
Issue number10
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Simvastatin
Tablets
Lipids
LDL Cholesterol
Double-Blind Method
Research Design
Cholesterol
Ezetimibe
Rosuvastatin Calcium
Safety

Keywords

  • Apolipoprotein B
  • CRP
  • Ezetimibe/simvastatin
  • HDL-C
  • Hypercholesterolemia
  • Lipids
  • Rosuvastatin
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. / Catapano, Alberico L.; Davidson, Michael H.; Ballantyne, Christie M.; Brady, William E.; Gazzara, Russell A.; Tomassini, Joanne E.; Tershakovec, Andrew M.

In: Current Medical Research and Opinion, Vol. 22, No. 10, 10.2006, p. 2041-2053.

Research output: Contribution to journalArticle

Catapano, Alberico L. ; Davidson, Michael H. ; Ballantyne, Christie M. ; Brady, William E. ; Gazzara, Russell A. ; Tomassini, Joanne E. ; Tershakovec, Andrew M. / Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. In: Current Medical Research and Opinion. 2006 ; Vol. 22, No. 10. pp. 2041-2053.
@article{fd7af841fd1b4e39a1051b550fda8bfc,
title = "Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients",
abstract = "Objective: assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. Research design and methods: Double-blind, multicenter, 6-week, parallel-group study in hypercholesterolemic patients (n = 2959). Patients were randomized based on stratification by low-density lipoprotein cholesterol (LDL-C) levels to ezetimibe/simvastatin or rosuvastatin, respectively, at the usual starting (10/20 or 10 mg/day), the next highest (10/40 or 20 mg/day), and maximum doses (10/80 or 40 mg/day). Results: At all doses and across doses, ezetimibe/simvastatin reduced LDL-C levels significantly more (52-61{\%}) than rosuvastatin (46-57{\%}; p ≤, 0.001). Significantly greater percentages of all patients (p <0.001) and high risk patients (p ≤, 0.005) attained LDL-C levels <70 mg/dL (1.8 mmol/L) following ezetimibe/simvastatin treatment compared with rosuvastatin at the prespecified doses and across doses. Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p <0.001), non-high-density lipoprotein cholesterol (p <0.001), lipid ratios (p",
keywords = "Apolipoprotein B, CRP, Ezetimibe/simvastatin, HDL-C, Hypercholesterolemia, Lipids, Rosuvastatin, Statins",
author = "Catapano, {Alberico L.} and Davidson, {Michael H.} and Ballantyne, {Christie M.} and Brady, {William E.} and Gazzara, {Russell A.} and Tomassini, {Joanne E.} and Tershakovec, {Andrew M.}",
year = "2006",
month = "10",
doi = "10.1185/030079906X132721",
language = "English",
volume = "22",
pages = "2041--2053",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients

AU - Catapano, Alberico L.

AU - Davidson, Michael H.

AU - Ballantyne, Christie M.

AU - Brady, William E.

AU - Gazzara, Russell A.

AU - Tomassini, Joanne E.

AU - Tershakovec, Andrew M.

PY - 2006/10

Y1 - 2006/10

N2 - Objective: assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. Research design and methods: Double-blind, multicenter, 6-week, parallel-group study in hypercholesterolemic patients (n = 2959). Patients were randomized based on stratification by low-density lipoprotein cholesterol (LDL-C) levels to ezetimibe/simvastatin or rosuvastatin, respectively, at the usual starting (10/20 or 10 mg/day), the next highest (10/40 or 20 mg/day), and maximum doses (10/80 or 40 mg/day). Results: At all doses and across doses, ezetimibe/simvastatin reduced LDL-C levels significantly more (52-61%) than rosuvastatin (46-57%; p ≤, 0.001). Significantly greater percentages of all patients (p <0.001) and high risk patients (p ≤, 0.005) attained LDL-C levels <70 mg/dL (1.8 mmol/L) following ezetimibe/simvastatin treatment compared with rosuvastatin at the prespecified doses and across doses. Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p <0.001), non-high-density lipoprotein cholesterol (p <0.001), lipid ratios (p

AB - Objective: assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. Research design and methods: Double-blind, multicenter, 6-week, parallel-group study in hypercholesterolemic patients (n = 2959). Patients were randomized based on stratification by low-density lipoprotein cholesterol (LDL-C) levels to ezetimibe/simvastatin or rosuvastatin, respectively, at the usual starting (10/20 or 10 mg/day), the next highest (10/40 or 20 mg/day), and maximum doses (10/80 or 40 mg/day). Results: At all doses and across doses, ezetimibe/simvastatin reduced LDL-C levels significantly more (52-61%) than rosuvastatin (46-57%; p ≤, 0.001). Significantly greater percentages of all patients (p <0.001) and high risk patients (p ≤, 0.005) attained LDL-C levels <70 mg/dL (1.8 mmol/L) following ezetimibe/simvastatin treatment compared with rosuvastatin at the prespecified doses and across doses. Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p <0.001), non-high-density lipoprotein cholesterol (p <0.001), lipid ratios (p

KW - Apolipoprotein B

KW - CRP

KW - Ezetimibe/simvastatin

KW - HDL-C

KW - Hypercholesterolemia

KW - Lipids

KW - Rosuvastatin

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=33750531657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750531657&partnerID=8YFLogxK

U2 - 10.1185/030079906X132721

DO - 10.1185/030079906X132721

M3 - Article

C2 - 17022864

AN - SCOPUS:33750531657

VL - 22

SP - 2041

EP - 2053

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 10

ER -